Strata Critical Medical (SRTA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for May 6, 2025, will be held virtually, allowing shareholders to vote and submit questions online.

• Key business includes electing three Class I directors, ratifying Deloitte & Touche LLP as auditor, and advisory votes on executive compensation and its frequency.

• Blade operates an asset-light air mobility model, focusing on medical organ transport and passenger services, with recent investments in owned aircraft for the Medical segment.

• The company is preparing for a transition to electric vertical aircraft (EVA) to reduce costs and emissions.

Voting matters and shareholder proposals

• Proposals include electing three Class I directors for terms expiring in 2028, ratifying Deloitte as auditor for 2025, advisory vote on executive compensation frequency, and advisory vote on executive compensation.

• Board recommends voting FOR all director nominees, FOR auditor ratification, FOR annual say-on-pay votes, and FOR executive compensation.

• Shareholders of record as of March 13, 2025, are eligible to vote.

Board of directors and corporate governance

• Board consists of eight directors divided into three classes with staggered three-year terms.

• Majority of directors are independent under Nasdaq rules; standing committees include Audit, Compensation, and Nominating and Corporate Governance.

• Board leadership separates CEO and Chair roles; regular board and committee self-assessments and succession planning are in place.

• Investor Rights Agreement and Nomination Rights Agreement provide certain shareholders with director nomination rights.